期刊
JOURNAL OF VIRAL HEPATITIS
卷 11, 期 1, 页码 69-73出版社
BLACKWELL PUBLISHING LTD
DOI: 10.1046/j.1365-2893.2003.00470.x
关键词
anti-HCV therapy; hepatitis C virus; interferon; thymosin
In this pilot study, we evaluated the efficacy of interferon-alpha (IFN) plus Thymosin-alpha 1 (TA1) to that of IFN alone in naive patients with chronic hepatitis C. Twenty-two patients were randomized to receive interferon-alpha(2b) (3 million units three times a week) plus thymosin-alpha l (900 mug/m(2) body surface area) and 19 received interferon-alpha(2b) alone at the same dose. Patients were treated for 6 months and followed up for another 6 months. Biochemical (alanine aminotransferase values) and virological (hepatitis C virus-RNA) responses to treatment were determined. Combination treatment showed significantly higher efficacy than monotherapy in achieving virological end-of-treatment response (P = 0.03). At 6-month follow up, the sustained biochemical and virological response was not different between the two groups. Our results indicate that the immune modulator TA1 may enhance the end-of-treatment response in naive patients with chronic hepatitis C. Higher doses and/ore more prolonged courses as well as the association with new interferon formulation such as pegylated interferons could improve the sustained response rates to this treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据